OM - NASDAQ
Outset Medical, Inc.
$4.60
-6.3%Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
At a Glance
Live SnapshotOutset Medical, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Outset Medical, Inc. Balance Sheet
OM • NASDAQ
| Outset Medical, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
35M | 124M | 68.5M | 73.2M | 182.3M | 295M | 36.9M | 33.3M | |
133.9M | 34.7M | 134.8M | 214.3M | 157.1M | 19.9M | 33.2M | 109.5M | |
168.9M | 158.7M | 203.3M | 287.5M | 339.5M | 314.9M | 70.1M | 142.8M | |
28.3M | 35.6M | 33M | 28.1M | 25.6M | 6.5M | 3.9M | 1.1M | |
28.3M | 35.6M | 33M | 28.1M | 25.6M | 6.5M | 3.9M | 1.1M | |
47.6M | 59.4M | 49.2M | 51.5M | 39.2M | 18.4M | 4.6M | 3M | |
0.0 | 0.0 | 0.0 | 0.0 | 5.5M | 0.0 | 1.1M | 754K | |
6M | 4.5M | 5.7M | 6.6M | 0.0 | 6.2M | 0.0 | 0.0 | |
250.9M | 258.2M | 291.2M | 373.6M | 409.8M | 345.9M | 79.6M | 147.6M | |
NON-CURRENT ASSETS | ||||||||
9.5M | 12.1M | 18.6M | 22M | 20.2M | 23.3M | 7.9M | 2.9M | |
3.8M | 0.0 | 0.0 | 3.3M | 33.3M | 0.0 | 743K | 151K | |
317K | 5.5M | 3.9M | 1.2M | 156K | 34.7M | 82K | 407K | |
13.6M | 17.6M | 22.6M | 26.5M | 53.7M | 57.9M | 8.7M | 3.5M | |
264.5M | 275.8M | 313.8M | 400.1M | 463.5M | 403.8M | 88.4M | 151.1M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
554K | 3.9M | 5.8M | 603K | 1.8M | 4.9M | 5M | 3.4M | |
554K | 3.9M | 5.8M | 603K | 1.8M | 4.9M | 5M | 3.4M | |
10.7M | 0.0 | 11.4M | 21.5M | 24.9M | 16.8M | 7M | 3.8M | |
1.7M | 1.8M | 0.0 | 0.0 | 0.0 | 0.0 | 7.5M | 10K | |
0.0 | 1.8M | 1.6M | 1.3M | 1.2M | 882K | 9K | 505K | |
13.8M | 12.8M | 11.7M | 8.7M | 6.3M | 3.2M | 883K | 269K | |
10.8M | 25.2M | 24.8M | 19.8M | 17.5M | 10.8M | 4.6M | 2.2M | |
37.6M | 45.4M | 55.3M | 51.9M | 51.7M | 36.7M | 24.9M | 10.2M | |
NON-CURRENT LIABILITIES | ||||||||
99.5M | 197.4M | 130.1M | 96.3M | 29.8M | 29.7M | 21.6M | 28.3M | |
406K | 844K | 101K | 151K | 312K | 570K | 134K | 13K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9K | |
-3.3M | 2.7M | 896K | 113K | 721K | 240K | 413.9M | 400.5M | |
99.9M | 203.6M | 135.6M | 102.2M | 37.7M | 38.5M | 435.6M | 428.9M | |
3.3M | 4.5M | 6.1M | 6.9M | 8M | 8.9M | 9K | 514K | |
137.5M | 249M | 190.9M | 154.1M | 89.4M | 75.2M | 460.6M | 439.1M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -356K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 409.4M | 392.3M | |
18K | 53K | 50K | 48K | 47K | 43K | 1K | 1K | |
1.3B | 1.1B | 1.1B | 1B | 1B | 822.6M | 356K | 0.0 | |
-1.2B | -1.1B | -961.7M | -789M | -626M | -494.1M | -372.6M | -287.9M | |
172K | 42K | 68K | -564K | -184K | 1K | 22K | -60K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -409.1M | -392.3M | |
127M | 26.8M | 122.9M | 246M | 374.1M | 328.6M | -372.2M | -288M | |
127M | 26.8M | 122.9M | 246M | 374.1M | 328.6M | -372.2M | -288M | |
SUMMARY | ||||||||
264.5M | 275.8M | 313.8M | 400.1M | 463.5M | 403.8M | 88.4M | 151.1M | |
137.8M | 34.7M | 134.8M | 217.6M | 190.5M | 19.9M | 33.2M | 109.5M | |
104.5M | 201.9M | 136.2M | 103.2M | 37.8M | 38.6M | 29.1M | 28.9M | |
69.5M | 77.8M | 67.7M | 30M | -144.5M | -256.4M | -7.9M | -4.4M | |
17,766,193 | 17,766,193 | 17,766,193 | 17,766,193 | 17,766,193 | 17,766,193 | 17,766,193 | 17,766,193 |
SEC Filings
OM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 26, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 27, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 07, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 |
Related Guides
Continue your OM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.